Nurix Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. (NRIX) on September 25, 2021. The filing discloses corporate governance changes, specifically the appointment of two new directors to the Board of Directors, effective October 1, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
The primary material change is the expansion of the Board of Directors with the addition of Judith A. Reinsdorf and Paul M. Silva. No financial or operational changes are reported in this filing.
Management Commentary and Compensation Details
The Board appointed Ms. Reinsdorf and Mr. Silva following a recommendation from the Nominating and Corporate Governance Committee. Their compensation includes:
- Cash Retainers: A pro rata portion of the $35,000 annual director retainer for the remainder of the fiscal year ending November 30, 2021.
- Committee Retainers: Ms. Reinsdorf receives a pro rata portion of the $4,000 Governance Committee retainer; Mr. Silva receives a pro rata portion of the $7,500 Audit Committee retainer.
- Initial Equity Award: Each director received a stock option to purchase 35,000 shares of common stock at the closing sale price on the grant date. These options vest monthly over three years.
- Annual Equity Award: Each director is eligible for an annual stock option to purchase 17,500 shares, vesting on the earlier of the next annual meeting or one year from the grant date.
- Acceleration: All awards accelerate in full upon the consummation of a Corporate Transaction.
Ms. Reinsdorf will serve as a Class II director (term expires 2022), and Mr. Silva will serve as a Class III director (term expires 2023). Both have entered into standard indemnification agreements.
Investor Verification Checklist
- Verify the closing stock price on September 25, 2021, to determine the exercise price of the 35,000 share options granted to each new director.
- Review the Company's 2020 Equity Incentive Plan to understand the specific definition of a "Corporate Transaction" that triggers award acceleration.
- Confirm the total number of outstanding shares and the dilution impact of the new director options relative to the company's capitalization.
- Check subsequent filings for the formal election of these directors at the upcoming annual meetings of stockholders.